Niki BioSolutions, Inc.
NIKI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$130.13K
Close$
$0.14
92.3% downside
Current Fair Value
92.3% downsideOvervalued by 92.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $130,127.00 |
|---|---|
| Enterprise Value | $1.80 Million |
| Earnings per Share | $-19 |
| Beta | 0.17 |
| Outstanding Shares | 73,518 |
Return
| Return on Equity | -7216.56% |
|---|---|
| Return on Assets | -19.80% |
| Return on Invested Capital | -14.44% |
Valuation & Multiples
| P/E Ratio | -0.09 |
|---|---|
| PEG | 1.11 |
| Price to Sales | - |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.99 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.94 |
| Debt to Equity | 74.65 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Aptorum Group Ltd
1 employees
CEO: Chung Yuen Huen
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its w...